Progesterone, progestins and the breast in menopause treatment.
Progesterone, progestins and the breast in menopause treatment.
Climacteric. 2018 Jun 01;:1-7
Authors: Gompel A, Plu-Bureau G
Abstract
Breast cancer is the main risk associated with menopause hormone therapy (MHT). It is a hormone-dependent cancer. In postmenopausal women, about 80% of cases are estradiol receptor-positive. In cohort studies only estradiol receptor-positive breast cancers are promoted by MHT. Different levels of risk with estrogen-only treatment and combined treatment with estrogen + progestin are shown in randomized trials and observational studies. Several non-randomized studies show a lower risk with progesterone and retroprogesterone than with synthetic progestins. Progesterone and progestin are non-selective ligands for the progesterone receptor and bind also with other steroid receptors, with agonistic or antagonistic effects according to the structure of the molecule. Their half-life and metabolism are also different, progesterone being rapidly degraded with a short half-life. These aspects will be discussed in this review.
PMID: 29852797 [PubMed - as supplied by publisher]
Source: Climacteric - Category: Geriatrics Authors: Gompel A, Plu-Bureau G Tags: Climacteric Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Estradiol | Geriatrics | Hormonal Therapy | Hormones | Men | Menopause | Study | Women